Young Women May Be Underrepresented In Breast Cancer Research Studies & Treatment

Main Category: Breast Cancer
Article Date: 07 Aug 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

While the incidence of breast cancer in young women in the U.S. is relatively rare, there are more than 250,000 women under the age of forty that are living with the disease and 11,000 will be diagnosed in the next year.

Television-star Christina Applegate's tumor was detected through magnetic resonance imaging, which was ordered by her doctor, according to her publicist. That decision proved lifesaving because the cancer was caught early when it is most likely to be treated and cured.

The highly sensitive MRI are very good at detecting tumors in young women whose dense breast tissue often hides tumors on mammogram X-rays. But it is also a very expensive procedure, one that all-too-frequently detects false abnormalities that necessitate biopsies. For this reason, the test is recommended only for those at increased risk of breast cancer. (Incidents of breast cancer is very uncommon in those under fifty, so most doctors do not screen women in their thirties.) News reports disclosed that Applegate's mother had previously battled breast cancer, but that by itself is not usually enough to justify an MRI in a woman so young.

According to genomic expert Simon Chin, young women are underrepresented in many research studies, as no effective screening tools exist and little research on genetic predisposition is available for this growing group of survivors. Mr. Chin leads the Iris BioTechnologies Cancer Analysis and Prevention Project at Santa Clara-based Iris BioTechnologies. He believes the project may be a good place for families to get personally involved in breast cancer prevention and the future of personalized medicine.

The online survey addresses not only family histories, but medical and lifestyle factors that are possible causative agents. By building personal medical and lifestyle family trees, women diagnosed with breast cancer will have valuable information at their fingertips to help their physicians make more personalized treatment decisions.

"Wouldn't it be nice if a majority survivors under the age of forty were able to build a database that might begin to uncover the intricacies of the disease? The time is now for prevention and cure to stand as equals," says Chin.

Mr. Chin, President, CEO and Founder and co-inventor of Iris's patented predictive medicine platform, is available for interviews. Mr. Chin has an MBA from Santa Clara University and a B.S. in Chemical Engineering from the University of California, Berkeley, where he was an Alumni Scholar. He is available to comment on the following:

-- How has the genome project opened a window onto various medical treatments?

-- Will we see personalized medicine in our lifetime?

-- How can technology help bridge the divide between genomics and personalized medicine?

-- How can young women benefit from the new technology?

-- How does the Iris technology work?

-- How can patients get involved?

Iris BioTechnologies
http://www.irisbiotech.com